Tags : Novel Therapies

Pharma

Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune

Shots: Evoq to receive ~$240M up front & milestones along with royalties on the sales of therapies emerges from the collaboration The companies collaborated on preclinical development, while Amgen will be responsible for clinical development and commercialization The collaboration will bolster Amgen’s autoimmune offerings as its portfolio contains innovative medicines, including Otezla and Enbrel, and […]Read More

Pharma

AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and

Shots: Frontier to receive$55M up front and is eligible for development & commercial milestone that could exceed $1B, along with royalties on commercialized products. The company might get ~45M within the first 12mos. of collaboration Following the completion of pre-clinical development, AbbVie will lead global development and commercialization activities and costs for the programs whereas […]Read More

Biotech

Genentech Collaborates with Scenic Biotech to Develop Novel Therapies Targeting

Shots: Scenic to receive ~$375M that includes up front, milestones along with royalties on sales of therapies emerges from the collaboration and will receive additional target fees for the therapies selected by Genentech The collaboration allows the Genentech to select multiple targets for further development with an option to extend the collaboration. Scenic will leverage […]Read More

Biotech

Roche Collaborates with Jnana Therapeutics to Discover Novel Therapies to

Shots: Jnana to receive $40M upfront payment in cash and is eligible to get ~$1B as research funding, preclinical, development, and commercialization milestone along with royalties on sales of the therapies The partners will work on the discovery and preclinical development of therapies targeting key regulators of cellular metabolism to treat across immunology and neuroscience […]Read More

Pharma

Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies

Shots: Dragonfly to receive ~ $47.5M up front, equity investment, development & commercial milestones along with royalties on sales of approved therapies Merck to get an option to license exclusive IP rights for multiple candidates developed using Dragonfly’s TriNKET technology platform for new targets in oncology, infectious disease, and immune disorders Dragonfly’s TriNKET technology act […]Read More

Pharma

LEO Pharma Signs an Option Agreement with Ubiquigent to Access

Shots: Ubiquigent to receive up front, option exercise fee and milestone payment. Leo Pharma to get an option to access two novel therapies The partnership will strengthen Leo Pharma’s research capabilities and disease understanding and extending its expertise in medical dermatology worldwide The option agreement follows 2018 agreement signed b/w Ubiquigent and LEO Pharma to […]Read More